Deals In Depth: July 2017
Executive Summary
AstraZeneca and Merck signed a broad targeted therapy and immuno-oncology alliance worth $8.5 billion; Japanese pharma Mitsubishi Tanabe boosted its neuroscience assets with the acquisition of NeuroDerm. Biopharma financing decreased from June, while device funding went up.